Retatrutide

Overview

Torsena is a European supplier of retatrutide research peptide dedicated to serving qualified laboratories and research institutions. Orders are shipped from EU-based stock with batch documentation available upon request. Single vials and bulk quantities are available for ongoing study protocols.

Lot & Supply Format

• Purity ≥99% verified by HPLC/MS analysis
• Mannitol-free formulation (no bulking agents or buffers)
• Lyophilized peptide in sealed glass research vials
• Single vials and bulk quantities available
• CoA transparency: batch-specific certificate of analysis available upon request
• Shipped from Europe with temperature-appropriate packaging

What is Retatrutide (LY3437943)?

Retatrutide research peptide (LY3437943) is a synthetic 39-amino acid peptide investigated in metabolic research as a triple receptor agonist. It exhibits simultaneous binding activity at three distinct targets:

GLP-1 Receptor — studied in incretin pathway signaling and glucose-dependent insulinotropic research models

GIP Receptor — investigated in complementary incretin signaling and nutrient-dependent metabolic pathway research

Glucagon Receptor — examined in energy balance modeling, hepatic lipid mobilization, and thermogenic signaling research

Retatrutide is the first compound to incorporate agonist activity across all three receptor systems within a single molecule, distinguishing it from dual-agonist compounds (tirzepatide: GLP-1 + GIP) and single-agonist compounds (semaglutide: GLP-1 alone). The compound includes a C18 fatty diacid modification facilitating albumin binding, extending its pharmacokinetic profile in experimental models.

Supplied exclusively for in-vitro and ex-vivo research by qualified laboratories. Not intended for human or animal administration.

Mechanistic Overview

GLP-1 Axis
Activates the glucagon-like peptide-1 receptor, a target extensively characterized in incretin signaling research. GLP-1 receptor activation has been studied in models examining glucose-dependent insulin secretion dynamics, gastric motility modulation, and central appetite signaling pathways.

GIP Axis
The glucose-dependent insulinotropic polypeptide receptor represents a complementary incretin target. In experimental settings, GIP receptor activation has been examined for its role in potentiating glucose-dependent signaling and synergistic effects when combined with GLP-1 pathway activation.

Glucagon Axis
The defining feature distinguishing retatrutide from other incretin-based research peptides. Glucagon receptor activation has been studied in models examining hepatic glycogenolysis, lipid oxidation pathways, and energy expenditure signaling. In preclinical research, glucagon axis engagement has been associated with increased energy utilization and modulation of lipid mobilization.

The convergence of all three receptor pathways within a single molecular scaffold provides researchers with a tool for investigating multi-receptor metabolic signaling interactions that cannot be replicated by combining individual single-target or dual-target agonists.

Published Research Data

Phase 2 clinical trial data published in peer-reviewed literature describes metabolic parameters observed with triple-agonist peptide compounds in controlled study populations. Researchers should consult primary sources for protocol design, model selection, and methodological parameters applicable to their investigations.

Key references:
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389(6):514-526.
Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544.

Retatrutide vs Tirzepatide vs Semaglutide

Characteristic	Retatrutide	Tirzepatide	Semaglutide
Receptor Targets	Triple: GLP-1, GIP, Glucagon	Dual: GLP-1, GIP	Single: GLP-1
Research Focus	Multi-receptor metabolic signaling	Dual incretin pathway research	GLP-1 signaling models
Molecular Length	39 amino acids	39 amino acids	31 amino acids
Acylation	C18 fatty diacid	C20 fatty diacid	C18 fatty diacid
Key Distinction	Glucagon axis activity	Dual incretin synergy	Well-characterized single pathway
CAS Number	2381089-83-2	2023788-19-2	910463-68-2

Why Choose Torsena for Retatrutide Research Peptide

• Analytical Testing — Purity verified by HPLC and mass spectrometry
• No Fillers — Mannitol-free, no bulking agents or buffer salts
• Transparency — Certificate of Analysis available upon request
• Consistent Availability — Single vials and bulk quantities maintained in stock
• EU Distribution — Shipped from European fulfillment with tracked courier
• Full Documentation — Batch-specific CoA and MSDS available for institutional procurement

Product Specifications

Chemical Name: Retatrutide
Synonyms: LY3437943
CAS Number: 2381089-83-2
Molecular Formula: C₂₂₁H₃₄₇N₅₁O₆₇S
Molecular Weight: ~4892.52 g/mol
Purity: ≥99% (HPLC/MS)
Physical Form: White to off-white lyophilized powder
Additives: None (mannitol-free)
Available Sizes: 5mg, 10mg, 15mg, 20mg, 24mg, 30mg
Intended Use: In-vitro / ex-vivo laboratory research only

Amino Acid Sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Tyr-Leu-Asp-Lys*-Ile-Ala-Gln-Arg-Ala-Phe-Val-Glu-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser

Modifications:
*Lys20 acylated with C18 fatty diacid
Aib = α-aminoisobutyric acid at position 2
Peptide Length: 39 amino acids
Type: Linear, acylated

Analytical Transparency

All Torsena research materials are tested for purity and identity by HPLC and mass spectrometry analysis. Batch-specific Certificates of Analysis are available upon request for institutional procurement.

Testing includes:

• Reverse-phase HPLC purity determination
• Mass spectrometry identity confirmation
• Appearance and solubility verification
• Endotoxin screening (where applicable)